Advanced company searchLink opens in new window

SYNEXUS CLINICAL RESEARCH MIDCO NO 2 LIMITED

Company number 07260768

Filter by category

Filter by category


Confirmation statement filters

Company Results (links open in a new window)
Date (document was filed at Companies House) Type Description (of the document filed at Companies House) View / Download (PDF file, link opens in new window)
10 May 2022 GAZ2(A) Final Gazette dissolved via voluntary strike-off
22 Feb 2022 GAZ1(A) First Gazette notice for voluntary strike-off
01 Feb 2022 DS01 Application to strike the company off the register
30 Dec 2021 AP01 Appointment of Mr Richard Stuart Harris as a director on 29 December 2021
30 Dec 2021 TM01 Termination of appointment of Brainard Judd Hartman as a director on 8 December 2021
01 Dec 2021 PSC05 Change of details for Synexus Clinical Research Midco No 1 Limited as a person with significant control on 1 September 2021
01 Dec 2021 AD01 Registered office address changed from Sandringham House Ackhurst Business Park, Foxhole Road Chorley Lancashire PR7 1NY to 12B Granta Park Great Abington, Cambridge CB21 6GQ on 1 December 2021
30 Nov 2021 GAZ1 First Gazette notice for compulsory strike-off
08 Jun 2021 CS01 Confirmation statement made on 21 May 2021 with no updates
07 Jan 2021 AA Full accounts made up to 31 December 2019
03 Jul 2020 AD02 Register inspection address has been changed to Eversheds Sutherland (International) Llp 70 Great Bridgewater Street Manchester M1 5ES
27 May 2020 CS01 Confirmation statement made on 21 May 2020 with no updates
13 Mar 2020 TM01 Termination of appointment of Christopher David Neild as a director on 13 March 2020
11 Oct 2019 AA Full accounts made up to 31 December 2018
29 May 2019 CS01 Confirmation statement made on 21 May 2019 with no updates
06 Oct 2018 AA Full accounts made up to 31 December 2017
24 May 2018 CS01 Confirmation statement made on 21 May 2018 with no updates
03 Oct 2017 AA Full accounts made up to 31 December 2016
26 May 2017 CS01 Confirmation statement made on 21 May 2017 with updates
31 Aug 2016 SH19 Statement of capital on 31 August 2016
  • GBP 3.02
31 Aug 2016 SH20 Statement by Directors
31 Aug 2016 CAP-SS Solvency Statement dated 31/08/16
31 Aug 2016 RESOLUTIONS Resolutions
  • RES13 ‐ The share premium account be reduced. 31/08/2016
  • RES06 ‐ Resolution of reduction in issued share capital
15 Jun 2016 AR01 Annual return made up to 21 May 2016 with full list of shareholders
Statement of capital on 2016-06-15
  • GBP 957,382.12
15 Jun 2016 TM01 Termination of appointment of Paul Michael Chambers as a director on 31 May 2016